The TWiST analysis of the phase III ENGOT-OV16/NOVA trial evaluated the time without symptoms or toxicity for niraparib vs placebo in patients with recurrent ovarian cancer.
The results of a post-hoc exploratory analysis of the phase III ARIEL3 trial were promising.
The phase II trial evaluated dendritic cell–based immunotherapy with concomitant administration of chemotherapy vs chemotherapy alone.
Avelumab alone or with pegylated liposomal doxorubicin did not improve survival in this phase III trial, but a subgroup analysis showed promising findings.
Results of a phase II trial evaluating pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide were presented at SGO 2019.
Early results of the WISP trial, which is evaluating risk-reducing salpingo-oophorectomy vs salpingectomy with delayed oophorectomy, were presented in Honolulu.
At SGO 2018, an early study showed ‘encouraging’ PFS with trastuzumab added to combination carboplatin/paclitaxel for advanced HER2/neu-overexpressing uterine serous carcinoma.
A study presented at the SGO Annual Meeting found that PARP-7 amplification mutations are associated with prolonged survival among patients with platinum-sensitive ovarian cancer.
An analysis presented at SGO 2018 concluded strong and consistent clinician recommendations might boost HPV vaccination rates among teens, particularly boys.
A study presented at the SGO Annual Meeting found that elderly women have higher rates of cervical cancer than previously thought, suggesting screening guidelines should be reconsidered.